RLMD - Relmada Therapeutics GAAP EPS of -$1.40 misses by $0.13

Relmada Therapeutics press release (NASDAQ:RLMD): Q1 GAAP EPS of -$1.40 misses by $0.13. As of Mar. 31, 2022, the company had cash, cash equivalents, and short-term investments of $220.6M, compared to cash, cash equivalents, and short-term investments of ~$211.9M at December 31, 2021. "We intend to generate REL-1017 clinical data readouts for the ongoing Reliance Phase 3 program beginning mid-year. We anticipate completing the enrollment of Reliance III, the ongoing monotherapy registrational Phase 3 trial and present the top-line results by mid-year 2022, followed by top-line results from Reliance I and Reliance II, the adjunctive MDD studies, throughout the second half of the year," CEO Sergio Traversa commented.

For further details see:

Relmada Therapeutics GAAP EPS of -$1.40 misses by $0.13